← Compound index
COMPOUND RECORD / HYPOXEN

Hypoxen / OlifenГипоксен / Олифен

Sodium polydihydroxyphenylene thiosulfonate, a synthetic sulfur-containing polymer formerly called Olifen. Researchers studied its effects under low-oxygen conditions.

PerformanceRecoveryStress
Source linked

What the studies found

Comparison in people · 2009

Psychological and psychomotor changes during heat exposure

Hypoxen · heat
Favorable subjective and mental work measures describedNo numerical effect, duration or arm sizes in the abstract.
Other arms
Different patterns under cold, heat and simulated altitudeCytoflavin, Reamberin and Mexidol are distinct comparators.

In a chamber study of healthy young men, Hypoxen was associated with psychological and psychomotor responses during heat exposure. Effects differed across drugs and environments.

Study notes · methods, sources and limitations

Participants or model Healthy men aged 20–24; Tabai chamber heat, cold and hypobaric hypoxia

Design Healthy men aged 20–24 in the Tabai thermobaric chamber; Hypoxen, Cytoflavin, Reamberin and Mexidol.

Important limitations

  • Noopept was not one of the tested drugs. Comparator allocation, effect sizes and adverse-event reporting require full-text review.
  • Preliminary chamber results. The authors’ recommendations are not verified worker protection.

Eksp Klin Farmakol. 72(6):36–41 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2021

Hypoxen: positive cold comparison, uncertain heat result

Study of multiple preparations

Hypoxen · hypoxia plus cold
10.0±0.9 versus 4.5±0.4 s; +120%Table 3; compared with stressed controlp=3×10⁻⁵
Hypoxen · hypoxia plus heat
22.7±3.5 versus 16.9±2.3 s; +34%Table 1; nonsignificant versus stressed controlp=0.18

In a mouse model, the Hypoxen cold result was significant; heat result was not. VIR-8 and the other groups are separate comparators.

Study notes · methods, sources and limitations

Participants or model Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia

Design Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia

Reported study exposure
50 mg/kg orally, once 1 hour before testing.

Important limitations

  • No verified human protection from environmental stress.
  • Each comparator used its own formulation, dose and schedule. The short mouse swim endpoint cannot establish human cold tolerance, prevention of heat injury or improved sports performance. The paper does not identify VIR-8 sequences or establish an identity match with PPK-V.
  • Retain the neutral heat result alongside the positive cold result. The model examines hemic hypoxia during temperature stress, not altitude acclimatization or actual outdoor work. The distinct products cannot be ranked as equivalent-dose interventions.

Biomeditsina. 17(1):57–69 · Original journal article

Original source or citation ↗

Study results and tables ↗

Lab research · 2010

The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases

Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.

Study notes · methods, sources and limitations

Participants or model Isolated rat liver mitochondria

Important limitations

  • Isolated organelles and experimental concentrations do not establish effects of oral use in humans. The translation and Russian paper are the same experiment.

Izv Akad Nauk Ser Biol. (4):411–416; English translation Biology Bulletin 37:346–350 · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Hypoxen / Olifen

Names in this research collection

Hypoxen · Hypoxenum · Gipoksen · Olifen · Олифен · Гипоксен · Polyfen · Polifen · Biotop · sodium polydihydroxyphenylene thiosulfonate

Identity / background source ↗

Research background

A synthetic polyphenolic preparation studied in hypoxia, environmental stress, exercise and cellular-energy metabolism. Human findings are limited, and laboratory effects depend on experimental conditions.

Russian ME/CFS and fatigue research ↗

More study findings

Study involving people · 2004

Changes in bioenergetic functions and performance capacity of athletes after administration of polyphenolic antihypoxic agents

Result availability
Numerical results not recoveredOriginal paper needed to verify the preparation, protocol, sample and effect size.

An indexed clinical-trial record connects the polyphenolic antihypoxant research to athlete bioenergetics. PubMed has no abstract; numerical performance claims are withheld pending original-text review.

Study notes · methods, sources and limitations

Participants or model Athletes; sample and allocation not recovered

Design Historical athlete bioenergetics publication.

Important limitations

  • Clinical Trial indexing does not establish randomization or methodological quality. Russian and English versions are one publication, not two studies.
  • Only the citation is available. It gives no measured outcome.

Fiziologiya Cheloveka. 30(2):101–109; English translation: Human Physiology 30:216–223 · Bibliographic lead

Original source or citation ↗

Study results and tables ↗

Animal research · 2002

Injection and oral pretreatment produced different results

Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.

Study notes · methods, sources and limitations

Participants or model C57BL/6 mouse bone-marrow chromosome-aberration assay

Important limitations

  • Route- and timing-dependent results; the oral negative finding must be retained. A mouse mutagen assay does not establish protection against industrial gases, benzene or cancer.

Experimental and Clinical Pharmacology. 65(3):54–56 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Polymeric antihypoxant
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Environmental and clinical comparisons; limited methodological detail

Study methods

Human comparisons, rat studies, mitochondrial assays and analytical chemistry

Independent replication

Independent clinical confirmation remains limited; historical cohorts may overlap

Source access

Indexed abstracts, publisher records, patent text and explicit archival leads

Safety evidence

Long-term and combination safety not established by this collection

Open a topic for the evidence assessment.

More findings, background and history
HYPOXEN / OLIFEN / UPDATED 4 OCTOBER 2026

Energy metabolism under stress

Hypoxen belongs to the antihypoxant research tradition: compounds investigated when oxygen availability or cellular energy production becomes limiting. Its polyphenolic chemistry differs from Bemitil’s benzimidazole structure and Bromantane’s adamantane structure. Shared research settings do not make these preparations interchangeable.

Educational only. Not medical advice. Seek qualified healthcare help for any medical condition. Occupational and toxicology research does not establish protection from hazardous exposure or replace gas detection, protective equipment, ventilation or emergency care.

Development history and original sources

Olifen is the earlier name linked to Hypoxen in the published literature. Biotop and Polyfen are retained as historical search terms; their formulation equivalence and the precise synthesis, authorization and renaming chronology still need original archival documents. The 2025 review identifies a substantial but difficult-to-access Military Medical Academy literature from the 1980s–1990s.

The bibliography includes Medvedev, Aleksandrova and Enokhin’s chemistry/mechanism work; Nasonkin, Kuzmich and Popov’s performance and clinical publications; Smirnov’s monograph; and the later mitochondrial work of Grishina, Maevsky, Kosenko and Murzaeva. Gutimine and Amtizol are related historical research branches, not established chemical ancestors of Hypoxen.

Study findings and limitations

BranchFinding or documentScope and limitations
Heat, cold and hypoxia2009 chamber comparison ↗: Hypoxen’s reported psychological and psychomotor effects were especially associated with heat exposure.Abstract-level evidence; effect sizes, allocation and safety need full-text appraisal.
Altitude comparison2014 altitude study ↗: Hypoxen served as a comparator to Metaprot–Ladasten and placebo.Comparison is not coadministration, and does not establish altitude-illness prevention.
Lactate and recovery2008 study ↗: a substrate–Hypoxen combination was associated with faster recovery-phase lactate utilization.Combination contribution and in-vivo sample remain unresolved from the abstract.
MitochondriaRespiration inhibition ↗ and low-concentration stimulation/channel findings ↗.Different concentrations, tissues and substrates. Neither supports a universal “oxygen booster” claim.
Clinical adjunct2012 postoperative comparison ↗: biochemical changes and less prolonged pain reported.52 treated versus 339 controls; allocation and baseline comparability unclear.
ToxicologyBednov’s gas-exposure experiment ↗ and route-dependent antimutagen assay ↗.Animal evidence. Oral pretreatment was negative in the antimutagen experiment; no benzene-protection claim is supported.

Historical combinations, separate levels of evidence

The Center for Extreme Medicine patent proposes support before, during and after extreme work. Hypoxen, Sydnocarb, Mebix, Deltoran and ascorbate appear in its phased protocol. It cites a 1999 Novikov–Shustov Academy document. This verifies an explicit proposal, not a clinically validated program.

The 2002 Navy diving-rule reproduction names piracetam and Olifen among recovery adjuncts after carbon-monoxide poisoning. The historical text is not a controlled study or current treatment advice.

Hypoxen plus aspirin is a separate rat inflammation experiment. Bromitil, the Bromantane–Bemitil combination, is a neighboring branch and does not contain Hypoxen. No convincing controlled human Hypoxen–Bemitil coadministration study has been verified in this collection.

View the historical combination records ↗

Modern analytical work and monitoring

The urinary-marker study was published online in 2024 and assigned to a 2025 journal issue. Detecting exposure is a different research question from demonstrating benefit. The official 2026 WADA Monitoring Program lists Hypoxen in and out of competition. Monitoring is distinct from prohibition and is not a safety endorsement. Status checked 4 October 2026.

Bibliography and original-source priorities

The 1999 athlete paper, 2001 monograph, early cardiovascular reports and original heat/altitude experiments remain important acquisition targets. Numerical tables reproduced in later accounts are not treated here as independently verified trial results.

2002

Russian Navy diving rules — historical Olifen recovery mention

Historical rule reproduction names piracetam, Olifen and vitamins during recovery after carbon-monoxide poisoning. It is not a comparative trial or current emergency-treatment guidance.

Bibliography & access details ↗
1999

Methods for optimizing functional state and human work capacity in extreme and subextreme conditions

Prior-art citation verified in the later patent. Original document not recovered; citation does not verify its clinical evidence.

Bibliography & access details ↗
2004

Bednov sulfur-containing-gas dissertation — author abstract PDF

PDF acquisition link from the source trail; scan not reviewed. The online transcription is separately appraised in hypoxen-bednov-2004.

Bibliography & access details ↗
2009

Meteoadaptogenic properties of antihypoxic drugs — publisher PDF

PDF located; abstract reviewed. Same source as antihypoxants-meteo-2009, not an additional trial.

Bibliography & access details ↗
2001

Hypoxen monograph

Secondary bibliography confirms the citation. Original monograph not recovered; page-count variants exist. Priority source for tracing older Olifen work.

Bibliography & access details ↗
2026

2026 WADA Monitoring Program

Hypoxen is monitored in and out of competition. Monitoring is distinct from prohibition and is not an endorsement of safety or efficacy. Checked 4 October 2026.

Bibliography & access details ↗
1999

Olifen: a new domestic means of increasing athletes’ physical work capacity

Reported citation: Vestnik Sportivnoy Meditsiny Rossii 24(3):43–44. Original article and sample details await recovery. Linked review is an entry point, not the original document.

Bibliography & access details ↗
1999

Antihypoxic activity and mechanism of action of Olifen

Reported conference abstract: Hypoxia: Mechanisms, Adaptation, Correction, Moscow, p. 5. Original proceedings await recovery. Linked review is an entry point, not the original document.

Bibliography & access details ↗
2003

Hypoxen and middle-/long-distance runner performance

The linked review cites this report. The original sample, allocation and overlap with the 2004 athlete study remain uncertain.

Bibliography & access details ↗
1993

Olifen in ischemic-heart-disease therapy

Clinical lineage lead; original methods, participant counts and outcomes require appraisal. Linked review is an entry point, not the original document.

Bibliography & access details ↗
1995

Olifen in combined therapy of angina pectoris

Adjunct-treatment citation trail; not yet an appraised clinical study. Linked review is an entry point, not the original document.

Bibliography & access details ↗
1996

Olifen and Amtizol in chronic circulatory failure

Original paper needed to distinguish comparison from coadministration. No combination efficacy claim is made. Linked review is an entry point, not the original document.

Bibliography & access details ↗
DATE UNRESOLVED

Original Olifen heat and 4,500-m altitude experiments

Numerical tables circulated in later sources need original samples, allocation, statistics and source-version checks. The reported percentages are not reproduced as verified effects. Linked review is an entry point, not the original document.

Bibliography & access details ↗
DATE UNRESOLVED

Biotop / Polyfen / Olifen development and Academy research archives

Original synthesis, 1988 authorization-related documents and the Rang-97/Biorhythmology project records remain acquisition targets. Shared institutions do not establish chemical descent or a single continuous program. Linked review is an entry point, not the original document.

Bibliography & access details ↗

Other leads that still need original sources

A reported 140-volunteer haemodynamic dataset, the Sydnocarb–Hypoxen combination, diclofenac experiments, leukocyte studies and proposed thiosulfate/Olifen/Elcar/Energostim mixtures require original methods and formulation checks. They remain research questions; the available sources do not establish effective or safe combinations. The same applies to exact Biotop/Polyfen formulation identity and claims of standard Soviet civil-defense use.

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2005 · EA005383B1 · Method of pharmacological correction of human work capacity in extreme situationsUse · No participant denominator, endpoint values or controlled effect estimate reported in the accessed description

The patent gives no measured outcomes

The accessed disclosure specifies a scheme but does not supply an extractable treatment cohort or measured comparative outcomes.

Clinical or performance results
No participant denominator, endpoint values or controlled effect estimate reported in the accessed descriptionThe claimed effectiveness is not a measured result
All reported results, comparisons and limitations →

Use. Hypoxen-related use under extreme conditions; patent examples are separate from controlled clinical confirmation.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
EA005383B1 ↗ · 2005-02-24
Earliest priority / filing
2001-12-28 / 2001-12-28
Original applicant / assignee
Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
34585798 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for pharmacological correction of human's efficiency under extreme conditions

Inventors: Евгений Георгиевич Жиляев; Павел Михайлович Шалимов; Дмитрий Валерьевич Глухов; Андрей Геннадьевич Жиляев; Сергей Егорович Макаров; Григорий Георгиевич Незнамов.

EA005383B1

Original patent PDF ↗

Read source review →

2003 · RU2205002C1 · Hypoxen: complement-pathway inhibition leadUse · Concentration-dependent inhibition of C1q-associated activity reported

Findings described in words

The experiments support a complement-interaction hypothesis rather than established clinical immune control.

C1q-related activity
Concentration-dependent inhibition of C1q-associated activity reportedLaboratory complement system, not autoimmune disease activity
Affinity-value ambiguity
The indexed text has an unclear exponent in the stated affinity value; no corrected binding constant is enteredAn OCR/exponent problem can change the value by many orders of magnitude
All reported results, comparisons and limitations →

Use. This use patent proposes Hypoxen in relation to C1q/C1 complement inhibition.

A mechanistic patent lead is not evidence of clinical autoimmune disease control or selective immune tolerance.

Publication
RU2205002C1 ↗ · 2003-05-27
Earliest priority / filing
2002-07-11 / 2002-07-11
Original applicant / assignee
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20255843 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Hypoxen as inhibitor of c1q subcomponent and c1 component of human complement system

Inventors: Б.Б. Шойбонов; А.Н. Онтобоев; А.А. Зинченко; В.А. Алёшкин.

RU2205002C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2021

VIR-8, Hypoxen and comparators under hypoxia with heat or cold

In a mouse model, the Hypoxen cold result was significant; heat result was not. VIR-8 and the other groups are separate comparators.

Study notes and original source
2021Animal / experimentalFull text available

VIR-8, Hypoxen and comparators under hypoxia with heat or cold

VIR-8 is a separately named polypeptide complex from Mobitek-M. Hypoxen, trimetazidine and food preparations were distinct arms. · Original journal article

Format: Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked · Reviewed: Reported methods, results and evidence limitations

E. B. Shustov, Yu. V. Fokin, S. L. Lyublinskiy, O. V. Alimkina, A. E. Kim, D. Yu. Ivkin, E. L. Matveenko, A. S. Ivkina, G. A. Plisko, M. A. Poveryaeva · Biomeditsina. 17(1):57–69

VIR-8 extended swimming under hypoxia plus cold (12.5±1.3 vs 4.5±0.4 seconds) but did not improve swimming under hypoxia plus heat (16.8±1.5 vs 16.9±2.3 seconds).

Results and tables

Reported findings and study design

VIR-8 extended swimming under hypoxia plus cold (12.5±1.3 vs 4.5±0.4 seconds) but did not improve swimming under hypoxia plus heat (16.8±1.5 vs 16.9±2.3 seconds).

Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia

Population or model Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia

Dose, route and schedule

VIR-8: 5 mg/kg rectally in 0.5 mL starch vehicle daily for 5 days. Hypoxen: 50 mg/kg orally by gavage once, 1 hour before testing. Sodium nitrite: 50 mg/kg intraperitoneally for hemic hypoxia. Main swim load: 5% body mass.

Protocol source ↗ · Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked

Results · Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked
MeasureResultComparison, timing and statistics
VIR-8 · hypoxia plus cold12.5±1.3 versus 4.5±0.4 s; +178%Table 3; compared with stressed control, n=10 per group · p=0.0002
VIR-8 · hypoxia plus heat16.8±1.5 versus 16.9±2.3 s; 0% reportedTable 1; compared with stressed control · p=0.99
VIR-8 · hypoxia at normal temperature29.8±4.2 versus 24.4±2.7 sTables 1 and 3 show the same thermoneutral series.
Hypoxen · hypoxia plus cold10.0±0.9 versus 4.5±0.4 s; +120%Table 3; compared with stressed control · p=3×10⁻⁵
Hypoxen · hypoxia plus heat22.7±3.5 versus 16.9±2.3 s; +34%Table 1; nonsignificant versus stressed control · p=0.18
Other arms · directional reversalFlamenco 50 mg/kg: −37% in heat, +111% in coldDifferent comparator preparation; not a VIR-8 result. Low-dose heat comparison p=0.02; cold p=2×10⁻¹² as printed.
Safety and sequenceNo human safety study or sequence-level characterization reportedThe designation VIR-8 is insufficient to infer constituent peptides.
Tables 1 and 3 · forced swimming across stress conditions
Tables 1 and 3 · forced swimming across stress conditions
GroupHypoxia, normal temperature (s)Hypoxia + heat (s)Heat effect vs controlHypoxia + cold (s)Cold effect vs control
Intact comparator72.6±7.063.5±7.9—5.6±0.7—
Stressed control24.4±2.716.9±2.3Reference4.5±0.4Reference
MioActive Sport24.8±2.716.9±1.3+2%; p=0.9918.4±1.5+308%; p=2×10⁻¹¹
VIR-829.8±4.216.8±1.50%; p=0.9912.5±1.3+178%; p=0.0002
Flamenco 50 mg/kg19.3±1.510.6±0.9−37%; p=0.029.5±1.1+111%; p=2×10⁻¹²
Flamenco 75 mg/kg21.5±5.014.6±1.8−14%; p=0.4312.9±0.8+187%; p=2×10⁻¹⁰
Flamenco 250 mg/kg20.7±2.834.4±4.7+104%; p=0.0036.9±1.0+53%; p=2×10⁻¹²
Trimetazidine22.7±11.187.3±18.2+418%; p=0.016.7±0.3+49%; p=2×10⁻¹⁷
Hypoxen30.1±4.322.7±3.5+34%; p=0.1810.0±0.9+120%; p=3×10⁻⁵

M±m and reported p-values transcribed from the article. Percentages are the authors’ reported changes relative to stressed controls, not comparisons between active arms. The intact groups do not receive hemic hypoxia; the displayed first column represents the relevant normothermic baseline.

Retain the neutral heat result alongside the positive cold result. The model examines hemic hypoxia during temperature stress, not altitude acclimatization or actual outdoor work. The distinct products cannot be ranked as equivalent-dose interventions.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Male outbred mice, 18–21 g; 10 randomized per group; loaded swim at 5% body mass after sodium nitrite-induced hemic hypoxia
Source reviewed
Original publisher issue PDF, printed pp. 57–69; methods and Tables 1 and 3 checked
Study limitations
  • Each comparator used its own formulation, dose and schedule.
  • The short mouse swim endpoint cannot establish human cold tolerance, prevention of heat injury or improved sports performance.
  • The paper does not identify VIR-8 sequences or establish an identity match with PPK-V.

Reviewed 2026-11-08.

Read the source ↗

Experiment described in a patent · 2003

Hypoxen: complement-pathway inhibition lead — RU2205002C1

The experiments support a complement-interaction hypothesis rather than established clinical immune control.

C1q-related activity · Concentration-dependent inhibition of C1q-associated activity reported · Laboratory complement system, not autoimmune disease activity

Study notes and original source
2003Patent / reported experimentsFull text available

Hypoxen: complement-pathway inhibition lead — RU2205002C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Б.Б. Шойбонов, А.Н. Онтобоев, А.А. Зинченко, В.А. Алёшкин · RU2205002C1 · patent family 20255843

The experiments support a complement-interaction hypothesis rather than established clinical immune control.

Results and tables

Reported patent results

Findings described in words

The experiments support a complement-interaction hypothesis rather than established clinical immune control.

Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.

Population or model Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.

Results · Binding experiments and narrative accompanying Tables 5–6; uncertain affinity exponent flagged.
MeasureResultComparison, timing and statistics
C1q-related activityConcentration-dependent inhibition of C1q-associated activity reportedLaboratory complement system, not autoimmune disease activity
Affinity-value ambiguityThe indexed text has an unclear exponent in the stated affinity value; no corrected binding constant is enteredAn OCR/exponent problem can change the value by many orders of magnitude

A biochemical inhibition result does not prove selective immune tolerance, clinical autoimmune efficacy or therapeutic safety.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Hypoxen in-vitro complement-binding and hemolytic-system experiments; no autoimmune patient treatment trial.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • A mechanistic patent lead is not evidence of clinical autoimmune disease control or selective immune tolerance.
  • A biochemical inhibition result does not prove selective immune tolerance, clinical autoimmune efficacy or therapeutic safety.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Review of earlier studies · 2025

A review of Hypoxen pharmacology and potential to enhance sports performance

The review identifies a difficult-to-access Military Medical Academy literature from the 1980s–1990s and limited human evidence. It discusses several mitochondrial mechanisms rather than establishing a single oxygen-boosting effect.

Study notes and original source
2025ReviewEnglish abstract

A review of Hypoxen pharmacology and potential to enhance sports performance

Format: Journal article · Reviewed: Abstract reviewed

K. Jędrejko, O. Catlin, R. Faiss, A. Pokrywka · Drug Testing and Analysis. 17(10):1896–1911

The review identifies a difficult-to-access Military Medical Academy literature from the 1980s–1990s and limited human evidence. It discusses several mitochondrial mechanisms rather than establishing a single oxygen-boosting effect.

Population / setting
Review of historical, experimental and human literature
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
  • A literature review is not independent replication.
  • The authors report a lack of clinical trials meeting international standards; historical use does not establish effectiveness or safety.

Reviewed 2026-10-04.

Read the source ↗

Study involving people · 2004

Changes in bioenergetic functions and performance capacity of athletes after administration of polyphenolic antihypoxic agents

An indexed clinical-trial record connects the polyphenolic antihypoxant research to athlete bioenergetics. PubMed has no abstract; numerical performance claims are withheld pending original-text review.

Study notes and original source
2004Human study · design details unresolvedBibliographic record

Changes in bioenergetic functions and performance capacity of athletes after administration of polyphenolic antihypoxic agents

Format: Journal article · Reviewed: Bibliographic metadata only

N. D. Altukhov, N. I. Volkov, S. L. Khoronyuk · Fiziologiya Cheloveka. 30(2):101–109; English translation: Human Physiology 30:216–223

An indexed clinical-trial record connects the polyphenolic antihypoxant research to athlete bioenergetics. PubMed has no abstract; numerical performance claims are withheld pending original-text review.

Results and tables

Reported findings and study design

Historical athlete bioenergetics publication.

Population or model Athletes; sample and allocation not recovered

Results · Original indexed bibliographic record, no abstract
MeasureResultComparison, timing and statistics
Result availabilityNumerical results not recoveredOriginal paper needed to verify the preparation, protocol, sample and effect size.

Only the citation is available. It gives no measured outcome.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Athletes; sample and allocation not recovered
Source reviewed
PubMed citation checked; full text and results not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
  • Clinical Trial indexing does not establish randomization or methodological quality.
  • Russian and English versions are one publication, not two studies.

Reviewed 2026-10-04.

Read the source ↗

Animal research · 2008

Accelerated utilization of lactate under the effect of hypoxen after intensive exercise

Hypoxen combined with energy-metabolism substrates was associated with higher lactate during maximal exercise, faster subsequent utilization and a lower recovery lactate/pyruvate ratio. The authors also describe an in-vitro NADH-oxidation pathway involving cytochrome c.

Study notes and original source
2008Animal / experimentalEnglish abstract

Accelerated utilization of lactate under the effect of hypoxen after intensive exercise

Format: Journal article · Reviewed: Abstract reviewed

E. V. Grishina, Ya. V. Khaustova, V. G. Pogorelova, A. G. Pogorelov, M. K. Kuzmich, E. I. Maevskii · Bulletin of Experimental Biology and Medicine. 145(2):198–201

Hypoxen combined with energy-metabolism substrates was associated with higher lactate during maximal exercise, faster subsequent utilization and a lower recovery lactate/pyruvate ratio. The authors also describe an in-vitro NADH-oxidation pathway involving cytochrome c.

Population / setting
Exercise experiment plus mitochondrial assays; in-vivo sample not specified in accessible abstract
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised. Study type is based on the database record and abstract, where available.
Study limitations
  • Combination exposure cannot isolate Hypoxen’s contribution.
  • The abstract does not establish the in-vivo species, sample, allocation or safety. This is not presented as a verified human recovery trial.

Reviewed 2026-10-04.

Read the source ↗

Lab research · 2010

The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases

Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.

Study notes and original source
2010In vitroEnglish abstract

The drug Hypoxen: a new inhibitor of mitochondrial respiration and dehydrogenases

Format: Journal article · Reviewed: Abstract reviewed

E. A. Kosenko, M. B. Abramova, N. I. Venediktova, I. I. Popova, Yu. G. Kaminskii · Izv Akad Nauk Ser Biol. (4):411–416; English translation Biology Bulletin 37:346–350

Hypoxen reduced phosphorylating and uncoupled respiration, with substrate-dependent concentration thresholds. Malate, glutamate and succinate dehydrogenase activities decreased. This qualifies the claim that it uniformly increases mitochondrial respiration.

Population / setting
Isolated rat liver mitochondria
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
  • Isolated organelles and experimental concentrations do not establish effects of oral use in humans.
  • The translation and Russian paper are the same experiment.

Reviewed 2026-10-04.

Read the source ↗

Lab research · 2010

Effect of Hypoxen on bioenergetic processes in mitochondria and ATP-sensitive potassium-channel activity

At low experimental concentrations, the authors report increased respiration, coupling, hydrogen-peroxide formation and potassium-associated mitochondrial swelling. ATP-related responses led them to propose involvement of mitochondrial ATP-sensitive potassium channels.

Study notes and original source
2010In vitroEnglish abstract

Effect of Hypoxen on bioenergetic processes in mitochondria and ATP-sensitive potassium-channel activity

Format: Journal article · Reviewed: Abstract reviewed

S. V. Murzaeva, M. B. Abramova, I. I. Popova, E. N. Gritsenko, G. D. Mironova, E. I. Lezhnev · Biofizika. 55(5):814–821; English translation Biophysics 55:727–732

At low experimental concentrations, the authors report increased respiration, coupling, hydrogen-peroxide formation and potassium-associated mitochondrial swelling. ATP-related responses led them to propose involvement of mitochondrial ATP-sensitive potassium channels.

Population / setting
Isolated rat heart and liver mitochondria
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
  • Concentration, substrate and tissue differ from the respiration-inhibition experiments.
  • Increased peroxide formation complicates a simple antioxidant narrative; these assays do not establish clinical benefit.

Reviewed 2026-10-04.

Read the source ↗

Comparison in people · 2012

Impact of Hypoxen therapy on postoperative course in gynecologic patients

An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.

Study notes and original source
2012Human comparative studyEnglish abstract

Impact of Hypoxen therapy on postoperative course in gynecologic patients

Format: Journal article · Reviewed: Abstract reviewed

M. Z. Dugieva, K. V. Kotenko, K. V. Morozova · Antibiotiki i Khimioterapiya. 57(5–6):28–31

An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.

Results and tables

Reported findings and study design

An observational postoperative comparison reported less prolonged pain with adjunctive Hypoxen, but did not give pain-event counts or an effect size.

52 Hypoxen recipients versus 339 routine-care controls after laparotomic gynecological surgery.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Prolonged postoperative painLower reported proportionHypoxen + routine care versus routine care · Early postoperative period · p<0.05, χ² test
Lipid oxidation and antioxidant measuresReported improvement; no numerical marker values in abstract
Group sizes52 adjunctive; 339 routine care

Unequal, non-randomized groups and absent event counts prevent calculation of absolute pain reduction or number needed to treat.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
52 adjunct-Hypoxen patients and 339 routine-care controls after abdominal gynecologic surgery
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
  • Very unequal group sizes; randomization, blinding and baseline comparability are not established.
  • No absolute pain-event counts in the abstract. Surgical findings do not establish sports, occupational or long-term safety benefits.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2002

Antimutagenic Hypoxen activity in vivo

Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.

Study notes and original source
2002Animal / experimentalEnglish abstract

Antimutagenic Hypoxen activity in vivo

Format: Journal article · Reviewed: Abstract reviewed

O. A. Karpova, L. V. Mikhina, A. A. Denisov, M. K. Kuzmich · Experimental and Clinical Pharmacology. 65(3):54–56

Simultaneous injected Hypoxen reduced dioxidine-associated genotoxicity by a reported 35% over 24 hours. Five-day oral pretreatment did not reduce damage.

Population / setting
C57BL/6 mouse bone-marrow chromosome-aberration assay
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
  • Route- and timing-dependent results; the oral negative finding must be retained.
  • A mouse mutagen assay does not establish protection against industrial gases, benzene or cancer.

Reviewed 2026-10-04.

Read the source ↗

Animal research · 2012

Influence of Metaprot and Hypoxen on inflammatory-reaction development in an experiment

Hypoxen and Metaprot showed weak anti-inflammatory activity alone but enhanced aspirin-associated effects. The publisher abstract identifies Hypoxen plus aspirin as the most effective combination tested.

Study notes and original source
2012Animal / experimentalEnglish abstract

Influence of Metaprot and Hypoxen on inflammatory-reaction development in an experiment

Format: Journal article · Reviewed: Abstract reviewed

V. E. Novikov, S. A. Ilyukhin, E. V. Pozhilova · Reviews on Clinical Pharmacology and Drug Therapy. 10(4):63–66

Hypoxen and Metaprot showed weak anti-inflammatory activity alone but enhanced aspirin-associated effects. The publisher abstract identifies Hypoxen plus aspirin as the most effective combination tested.

Population / setting
Carrageenan-induced rat paw inflammation
Source reviewed
Indexed or publisher abstract reviewed; full methods and risk of bias not appraised.
Study limitations
  • Animal inflammation endpoints are not human analgesic or performance outcomes.
  • The abstract wording does not establish a Hypoxen-plus-Bemitil performance regimen. Full arm definitions and safety require review.

Reviewed 2026-10-04.

Read the source ↗

Animal research · 2004

Physiological mechanisms of chronic exposure to sulfur-containing gas in an experiment

The author’s conclusions report lower lipid-peroxidation, hypoxia and endogenous-intoxication markers and a shorter recovery period with Olifen. The industrial-gas context concerns the Astrakhan program, but the intervention evidence here is animal work.

Study notes and original source
2004Animal / experimentalRussian-language source

Physiological mechanisms of chronic exposure to sulfur-containing gas in an experiment

Format: Dissertation abstract reproduction · Reviewed: Relevant conclusions and catalogue checked

I. A. Bednov · Candidate biological-sciences dissertation, Astrakhan, 143 pages; author-abstract reproduction

The author’s conclusions report lower lipid-peroxidation, hypoxia and endogenous-intoxication markers and a shorter recovery period with Olifen. The industrial-gas context concerns the Astrakhan program, but the intervention evidence here is animal work.

Population / setting
Rats exposed chronically to sulfur-containing gas standardized to 3 mg/m³ hydrogen sulfide
Source reviewed
Online author-abstract reproduction reviewed; original experimental tables remain to be recovered.
Study limitations
  • Author-abstract transcription, not the full 143-page dissertation.
  • Mixed industrial gas is not equivalent to pure H₂S or benzene; no protective effect in exposed workers is established.

Reviewed 2026-10-04.

Read the source ↗

Experiment described in a patent · 2005

Method of pharmacological correction of human work capacity in extreme situations

The patent organizes pharmacological support before exposure, during work and after work. It names Hypoxen, Sydnocarb, Mebix, Deltoran and ascorbate in the first phases, with symptom-dependent changes.

Study notes and original source
2005Patent / reported experimentsFull text available

Method of pharmacological correction of human work capacity in extreme situations

Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

E. G. Zhilyaev, P. M. Shalimov, D. V. Glukhov, A. G. Zhilyaev, S. E. Makarov, G. G. Neznamov · EA005383B1. Filed 28 December 2001; published 24 February 2005. Center for Extreme Medicine

The patent organizes pharmacological support before exposure, during work and after work. It names Hypoxen, Sydnocarb, Mebix, Deltoran and ascorbate in the first phases, with symptom-dependent changes.

Results and tables

Reported patent results

The patent gives no measured outcomes

The accessed disclosure specifies a scheme but does not supply an extractable treatment cohort or measured comparative outcomes.

A staged pharmacological-support method for work under extreme conditions; multiple agents are proposed at different stages.

Population or model A staged pharmacological-support method for work under extreme conditions; multiple agents are proposed at different stages.

Results · Entire accessed description: staged scheme and concluding rationale.
MeasureResultComparison, timing and statistics
Clinical or performance resultsNo participant denominator, endpoint values or controlled effect estimate reported in the accessed descriptionThe claimed effectiveness is not a measured result

Hypoxen is one component of a proposed multi-agent approach. A regimen and its claimed benefits cannot be substituted for experimental or clinical data.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
A staged pharmacological-support method for work under extreme conditions; multiple agents are proposed at different stages.
Source reviewed
Claims, description, filing dates and prior-art citation reviewed.
Study limitations
  • A patent documents a proposal, not a validated regimen, implemented service-wide doctrine or controlled trial.
  • The document cites a 1999 Academy publication by Novikov and Shustov. Its full text is unavailable here.

Reviewed 2026-11-06.

Read the source ↗

Laboratory analysis · 2025

Urinary metabolites indicative of Hypoxen administration monitored by LC–HRMS/MS

The analytical study identified eight plausible Hypoxen-related urinary analytes. It provides markers for detecting administration, not evidence of improved endurance or clinical effectiveness.

Study notes and original source
2025Analytical / composition studyFull text available

Urinary metabolites indicative of Hypoxen administration monitored by LC–HRMS/MS

Format: Journal article · Reviewed: Publisher methods and results reviewed

C. Görgens, T. Möller, S. Guddat, and colleagues · Drug Testing and Analysis. 17(2):225–230; first published online 23 April 2024

The analytical study identified eight plausible Hypoxen-related urinary analytes. It provides markers for detecting administration, not evidence of improved endurance or clinical effectiveness.

Population / setting
Exploratory post-administration urine analysis
Source reviewed
Publisher analytical report reviewed; chemical assignments are reported at the authors’ stated certainty.
Study limitations
  • Tentative metabolite assignments and exploratory sampling limit interpretation.
  • Detection of use is distinct from proof of efficacy, safety or a doping-rule violation.

Reviewed 2026-10-04.

Read the source ↗

Comparison in people · 2014

Possibilities of the pharmacological correction of adaptive reactions of human organism in short-term moving from middle to high altitude]

An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.

Study notes and original source
2014Human comparative studyEnglish abstract

Possibilities of the pharmacological correction of adaptive reactions of human organism in short-term moving from middle to high altitude]

Kundashev UK, Zurdinov AZ, Barchukov VG · Eksperimental'naia i klinicheskaia farmakologiia 77(9):32-37. PMID 25365868

An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.

Results and tables

Reported findings and study design

An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.

Volunteers acclimatized for 15 days at 1,670 m before moving to 3,750 m; group sizes not supplied.

Population or model Volunteers moving from 1,670 m to 3,750 m after 15 days at middle altitude

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Adaptation timingCombination: within first hours; Hypoxen: by day 3; placebo: still developing on day 3Authors’ descriptive metabolic time course, not a timed endurance effect
Exercise tolerance and blood-cell measuresReported stronger responses with the combinationNo absolute work or blood-cell effect sizes supplied
Studied armsMetaprot 0.125 g + Ladasten 0.1 g; Hypoxen 0.5 g; placeboCombination effect cannot be assigned to either component alone

No component-only arms are described in the abstract. Earlier metabolic adaptation does not establish safe high-altitude use or independent bromantane efficacy.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Volunteers moving from 1,670 m to 3,750 m after 15 days at middle altitude
Source reviewed
Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
  • No single-component arms are described, so the study cannot isolate contributions or establish synergy.
  • Enrollment and allocation details require full-text review.
  • Not a validated altitude-illness prevention strategy.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 2009

Meteoadaptogenic properties of antihypoxants

In a chamber study of healthy young men, Hypoxen was associated with psychological and psychomotor responses during heat exposure. Effects differed across drugs and environments.

Study notes and original source
2009Human comparative studyEnglish abstract

Meteoadaptogenic properties of antihypoxants

V. P. Ganapolsky, P. D. Shabanov · Eksp Klin Farmakol. 72(6):36–41

The healthy-volunteer chamber comparison reports environment-dependent effects. Hypoxen was associated with psychological and psychomotor responses during heat exposure; benefits were not uniform across the four agents and three environments.

Results and tables

Reported findings and study design

Healthy men aged 20–24 in the Tabai thermobaric chamber; Hypoxen, Cytoflavin, Reamberin and Mexidol.

Population or model Healthy men aged 20–24; Tabai chamber heat, cold and hypobaric hypoxia

Results · Publisher abstract; numerical tables unavailable
MeasureResultComparison, timing and statistics
Hypoxen · heatFavorable subjective and mental work measures describedNo numerical effect, duration or arm sizes in the abstract.
Other armsDifferent patterns under cold, heat and simulated altitudeCytoflavin, Reamberin and Mexidol are distinct comparators.

Preliminary chamber results. The authors’ recommendations are not verified worker protection.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Healthy men aged 20–24; Tabai chamber heat, cold and hypobaric hypoxia
Source reviewed
Russian primary-publisher abstract and DOI checked; full text not reviewed.
Study limitations
  • Noopept was not one of the tested drugs.
  • Comparator allocation, effect sizes and adverse-event reporting require full-text review.

Reviewed 2026-10-04.

Read the source ↗

Explore related historical combinations ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗